Cleared Traditional

K904022 - NITRO BLUE TETRAZOLIUM REDUCTION

K904022 is an FDA 510(k) clearance for NITRO BLUE TETRAZOLIUM REDUCTION, manufactured by Sigma Chemical Co.. The device is a Class 1 Pathology device with product code GHD cleared through the Traditional 510(k) pathway after a 110-day FDA review.

K904022 · Sigma Chemical Co. · Pathology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1990
Decision
110d
Days
Class 1
Risk

K904022 is an FDA 510(k) clearance for the NITRO BLUE TETRAZOLIUM REDUCTION. Classified as Test, Leukocyte Alkaline Phosphatase (product code GHD), Class I - General Controls.

Submitted by Sigma Chemical Co. (St. Louis, US). The FDA issued a Cleared decision on December 18, 1990 after a review of 110 days - within the typical 510(k) review window.

This device falls under the Pathology FDA review panel, regulated under 21 CFR 864.7660 - the FDA pathology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Pathology review framework, consistent with the majority of Class II 510(k) submissions.

View all Sigma Chemical Co. devices

FDA 510(k) Submission Details - K904022

510(k) Number K904022 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 30, 1990
Decision Date December 18, 1990
Days to Decision 110 days
Submission Type Traditional
Review Panel Pathology (PA)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
33d slower than avg
Panel avg: 77d · This submission: 110d
Pathway characteristics
Predicate-based equivalence.

GHD Device Classification - Class 1, General Controls

Product Code GHD Test, Leukocyte Alkaline Phosphatase
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 864.7660
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.